536350291	536350291	CD	B-NP	O
|	|	NN	I-NP	O
N	N	NN	I-NP	O
|	|	VBD	B-VP	O
73737688	73737688	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
8585316	8585316	CD	B-NP	O
|	|	CC	I-NP	O
4/13/2005	4/13/2005	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
ASTHMA	ASTHMA	NNP	I-NP	I-protein
FLARE	FLARE	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Unsigned	Unsigned	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
4/13/2005	4/13/2005	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Unsigned	Unsigned	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
1/13/2006	1/13/2006	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
HICKAM	HICKAM	NN	B-NP	O
,	,	,	O	O
TOM	TOM	NNP	B-NP	O
SIMON	SIMON	NNP	I-NP	O
MD	MD	NNP	I-NP	O
PRIMARY	PRIMARY	NNP	I-NP	O
CARE	CARE	NNP	I-NP	O
PHYSICIAN	PHYSICIAN	NNP	I-NP	O
:	:	:	O	O
Jason	Jason	NNP	B-NP	O
Vanwechel	Vanwechel	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
Chronic	Chronic	JJ	B-NP	O
obstructive	obstructive	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
disease	disease	NN	I-NP	O
exacerbation	exacerbation	NN	I-NP	O
.	.	.	O	O

SECONDARY	SECONDARY	NN	B-NP	O
DIAGNOSES	DIAGNOSES	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Acute-on-chronic	Acute-on-chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Congestive	Congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Diabetes	Diabete	NNS	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

History	History	NN	B-NP	O
of	of	IN	B-PP	O
upper	upper	JJ	B-NP	O
gastrointestinal	gastrointestinal	JJ	I-NP	O
bleed	bleed	NN	I-NP	O
.	.	.	O	O

CHIEF	CHIEF	NN	B-NP	B-protein
COMPLAINT	COMPLAINT	NN	I-NP	O
:	:	:	O	O
Shortness	Shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
65-year-old	65-year-old	JJ	I-NP	O
gentleman	gentleman	NN	I-NP	O
with	with	IN	B-PP	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
COPD	COPD	NN	B-NP	O
,	,	,	O	O
CHF	CHF	NN	B-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
stage	stage	NN	B-NP	O
IV	IV	CD	I-NP	O
chronic	chronic	JJ	I-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
presented	present	VBD	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
room	room	NN	I-NP	O
on	on	IN	B-PP	O
8/26/2005	8/26/2005	CD	B-NP	O
with	with	IN	B-PP	O
wheezing	wheezing	NN	B-NP	O
and	and	CC	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
following	follow	VBG	B-PP	O
a	a	DT	B-NP	O
three-day	three-day	JJ	I-NP	O
prodrome	prodrome	NN	I-NP	O
of	of	IN	B-PP	O
cough	cough	NN	B-NP	O
,	,	,	O	O
congestion	congestion	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
chills	chill	NNS	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
room	room	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
BNP	BNP	NN	I-NP	B-protein
of	of	IN	B-PP	O
519	519	CD	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
Lasix	Lasix	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
room	room	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
point	point	NN	I-NP	O
for	for	IN	B-PP	O
diagnosis	diagnosis	NN	B-NP	O
of	of	IN	B-PP	O
COPD	COPD	NN	B-NP	O
exacerbation	exacerbation	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
an	an	DT	B-NP	O
upper	upper	JJ	I-NP	O
respiratory	respiratory	JJ	I-NP	O
infection	infection	NN	I-NP	O
in	in	IN	B-PP	O
addition	addition	NN	B-NP	O
to	to	TO	B-PP	O
mild	mild	JJ	B-NP	O
congestive	congestive	JJ	I-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
oral	oral	JJ	B-NP	O
glucocorticoids	glucocorticoid	NNS	I-NP	O
and	and	CC	O	O
frequent	frequent	JJ	B-NP	O
bronchodilator	bronchodilator	NN	I-NP	O
therapy	therapy	NN	I-NP	O
was	be	VBD	B-VP	O
initiated	initiate	VBN	I-VP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
mental	mental	JJ	I-NP	O
status	status	NN	I-NP	O
began	begin	VBD	B-VP	O
to	to	TO	I-VP	O
rapidly	rapidly	RB	I-VP	O
decline	decline	VB	I-VP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
he	he	PRP	B-NP	O
became	become	VBD	B-VP	O
more	more	RBR	B-ADJP	O
somnolent	somnolent	JJ	I-ADJP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
ABG	ABG	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
pH	pH	NN	I-NP	O
of	of	IN	B-PP	O
7.16	7.16	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
then	then	RB	I-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
ICU	ICU	NN	I-NP	O
for	for	IN	B-PP	O
hypercarbic	hypercarbic	JJ	B-NP	O
respiratory	respiratory	JJ	I-NP	O
failure	failure	NN	I-NP	O
after	after	IN	B-PP	O
failing	fail	VBG	B-VP	O
an	an	DT	B-NP	O
initial	initial	JJ	I-NP	O
trial	trial	NN	I-NP	O
of	of	IN	B-PP	O
BiPAP	BiPAP	NN	B-NP	B-protein
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
COPD	COPD	NN	B-NP	O
,	,	,	O	O
requiring	require	VBG	B-VP	O
at	at	IN	B-NP	O
least	least	JJS	I-NP	O
two	two	CD	I-NP	O
prior	prior	JJ	I-NP	O
intubations	intubation	NNS	I-NP	O
;	;	:	O	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
,	,	,	O	O
previously	previously	RB	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
diastolic	diastolic	JJ	B-ADJP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	O
of	of	IN	B-PP	O
50	50	CD	B-NP	O
%	%	NN	I-NP	O
;	;	:	O	O
diabetes	diabete	NNS	B-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
upper	upper	JJ	B-NP	O
GI	GI	NN	I-NP	O
bleed	bleed	NN	I-NP	O
in	in	IN	B-PP	O
5/20	5/20	CD	B-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
an	an	DT	B-NP	O
antral	antral	JJ	I-NP	O
ulcer	ulcer	NN	I-NP	O
,	,	,	O	O
pneumonia	pneumonia	NN	B-NP	O
in	in	IN	B-PP	O
7/20	7/20	CD	B-NP	O
left	leave	VBD	B-VP	O
lower	low	JJR	B-NP	O
lobe	lobe	NN	I-NP	O
nodule	nodule	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
stable	stable	JJ	B-ADJP	O
on	on	IN	B-PP	O
followup	followup	NN	B-NP	O
CTs	CT	NNS	I-NP	O
;	;	:	O	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
thought	think	VBD	B-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
diabetes	diabetes	NN	B-NP	O
and	and	CC	I-NP	O
hypertension	hypertension	NN	I-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
former	former	JJ	I-NP	O
smoker	smoker	NN	I-NP	O
with	with	IN	B-PP	O
rare	rare	JJ	B-NP	O
alcohol	alcohol	NN	I-NP	O
use	use	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
lives	live	VBZ	B-VP	O
alone	alone	RB	B-ADVP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
retired	retired	JJ	I-NP	B-protein
chef	chef	NN	I-NP	I-protein
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Mother	Mother	NNP	B-NP	O
died	die	VBD	B-VP	O
of	of	IN	B-PP	O
diabetes	diabete	NNS	B-NP	O
.	.	.	O	O

Father	Father	NNP	B-NP	O
had	have	VBD	B-VP	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

Brother	Brother	NNP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
pituitary	pituitary	JJ	B-NP	O
cancer	cancer	NN	I-NP	O
and	and	CC	O	O
another	another	DT	B-NP	O
brother	brother	NN	I-NP	O
with	with	IN	B-PP	O
lymphoma	lymphoma	NN	B-NP	O
.	.	.	O	O

HOME	HOME	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Amiloride	Amiloride	IN	B-PP	O
5	5	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
2	2	CD	I-NP	O
.	.	.	O	O

Clonodine	Clonodine	NN	B-NP	O
7.5	7.5	CD	I-NP	O
mg	mg	NN	I-NP	O
topically	topically	RB	B-ADVP	O
weekly	weekly	RB	I-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Hydrochlorothiazide	Hydrochlorothiazide	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Lisinopril	Lisinopril	NNP	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
5	5	CD	I-NP	O
.	.	.	O	O

Lasix	Lasix	NN	B-NP	B-protein
160	160	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
6	6	CD	I-NP	I-protein
.	.	.	O	O

Labetalol	Labetalol	NN	B-NP	B-protein
600	600	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
7	7	CD	I-NP	I-protein
.	.	.	O	O

NPH	NPH	NN	B-NP	B-protein
25	25	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
in	in	IN	B-PP	O
the	the	DT	B-NP	O
morning	morning	NN	I-NP	O
and	and	CC	O	O
15	15	CD	B-NP	O
units	unit	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
evening	evening	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Calcitriol	Calcitriol	NN	B-NP	O
0.25	0.25	CD	I-NP	O
mcg	mcg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Advair	Advair	NN	B-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Albuterol/Combivent	Albuterol/Combivent	NNP	B-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
IBUPROFEN	IBUPROFEN	NNP	B-NP	O
WITH	WITH	NNP	I-NP	O
WORSENING	WORSENING	NNP	I-NP	O
RENAL	RENAL	NNP	I-NP	O
FAILURE	FAILURE	NNP	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NNP	B-NP	O
EXAMINATION	EXAMINATION	NNP	I-NP	O
UPON	UPON	NNP	I-NP	O
ADMISSION	ADMISSION	NNP	I-NP	O
:	:	:	O	O
Temperature	Temperature	NN	B-NP	O
100.6	100.6	CD	I-NP	O
,	,	,	O	O
heart	heart	NN	B-NP	O
rate	rate	NN	I-NP	O
88	88	CD	I-NP	O
,	,	,	O	O
respiratory	respiratory	JJ	B-NP	O
rate	rate	NN	I-NP	O
28	28	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
158/90	158/90	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
saturating	saturate	VBG	B-VP	O
99	99	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
2	2	CD	B-NP	O
L	L	NN	I-NP	O
nasal	nasal	JJ	I-NP	O
cannula	cannula	NN	I-NP	O
.	.	.	O	O

General	General	NNP	B-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
pleasant	pleasant	NN	I-NP	O
,	,	,	O	O
mildly	mildly	RB	B-NP	O
overweight	overweight	JJ	I-NP	O
African-American	African-American	JJ	I-NP	O
male	male	NN	I-NP	O
visibly	visibly	RB	B-VP	O
wheezing	wheeze	VBG	I-VP	O
and	and	CC	I-VP	O
speaking	speak	VBG	I-VP	O
in	in	IN	B-PP	O
short	short	JJ	B-NP	O
phrases	phrase	NNS	I-NP	O
.	.	.	O	O

HEENT	HEENT	NN	B-NP	O
:	:	:	O	O
Pupils	Pupil	NNS	B-NP	O
are	be	VBP	B-VP	O
equal	equal	JJ	B-ADJP	O
,	,	,	O	O
round	round	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
reactive	reactive	JJ	B-ADJP	O
to	to	TO	B-PP	O
light	light	NN	B-NP	O
.	.	.	O	O

Oropharynx	Oropharynx	NNP	B-NP	O
is	be	VBZ	B-VP	O
clear	clear	JJ	B-ADJP	O
.	.	.	O	O

Neck	Neck	NNP	B-NP	O
:	:	:	O	O
Supple	Supple	NNP	B-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
lymphadenopathy	lymphadenopathy	NN	I-NP	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
Tachycardic	Tachycardic	JJ	B-ADJP	O
.	.	.	O	O

No	No	DT	B-NP	O
murmurs	murmur	NNS	I-NP	O
,	,	,	O	O
rubs	rub	NNS	B-NP	O
,	,	,	O	O
or	or	CC	O	O
gallops	gallop	NNS	B-NP	O
.	.	.	O	O

JVP	JVP	NN	B-NP	B-protein
was	be	VBD	B-VP	O
increased	increase	VBN	I-VP	O
.	.	.	O	O

Respiratory	Respiratory	NNP	B-NP	O
:	:	:	O	O
Crackles	Crackles	NNP	B-NP	O
,	,	,	O	O
bibasilar	bibasilar	JJ	B-ADJP	O
.	.	.	O	O

Notable	Notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
diffuse	diffuse	JJ	B-NP	O
wheezes	wheeze	NNS	I-NP	O
.	.	.	O	O

Minimal	Minimal	JJ	B-NP	O
air	air	NN	I-NP	O
movement	movement	NN	I-NP	O
.	.	.	O	O

Peak	Peak	NN	B-NP	O
flow	flow	NN	I-NP	O
was	be	VBD	B-VP	O
measured	measure	VBN	I-VP	O
at	at	IN	B-PP	O
200	200	CD	B-NP	O
.	.	.	O	O

Abdomen	Abdoman	NNS	B-NP	O
:	:	:	O	O
Soft	Soft	NNP	B-NP	O
,	,	,	O	O
nontender	nontender	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
nondistended	nondistended	JJ	B-ADJP	O
.	.	.	O	O

Bowel	Bowel	NN	B-NP	O
sounds	sound	NNS	I-NP	O
are	be	VBP	B-VP	O
present	present	JJ	B-ADJP	O
.	.	.	O	O

Extremities	Extremity	NNS	B-NP	O
:	:	:	O	O
Mild	Mild	JJ	B-NP	O
clubbing	clubbing	NN	I-NP	O
and	and	CC	I-NP	O
trace	trace	NN	I-NP	O
edema	edema	NN	I-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
STUDIES	STUDIES	NNS	I-NP	O
UPON	UPON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
Notable	Notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
electrolyte	electrolyte	NN	B-NP	O
panel	panel	NN	I-NP	O
within	within	IN	B-PP	O
normal	normal	JJ	B-NP	O
limits	limit	NNS	I-NP	O
.	.	.	O	O

BUN	BUN	NN	B-NP	O
of	of	IN	B-PP	O
52	52	CD	B-NP	O
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
of	of	IN	B-PP	O
3.3	3.3	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
glucose	glucose	NN	B-NP	O
of	of	IN	B-PP	O
154	154	CD	B-NP	O
.	.	.	O	O

BNP	BNP	NN	B-NP	B-protein
was	be	VBD	B-VP	O
317	317	CD	B-NP	O
.	.	.	O	O

Hemogram	Hemogram	NN	B-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
white	white	JJ	I-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
7.7	7.7	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
40.6	40.6	CD	I-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
platelets	platelet	NNS	B-NP	B-cell_type
219	219	CD	B-NP	O
.	.	.	O	O

MCV	MCV	NN	B-NP	O
was	be	VBD	B-VP	O
low	low	JJ	B-ADJP	O
at	at	IN	B-PP	O
80	80	CD	B-NP	O
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
showed	show	VBD	B-VP	O
interstitial	interstitial	JJ	B-NP	O
edema	edema	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
infiltrates	infiltrate	NNS	I-NP	O
.	.	.	O	O

EKG	EKG	NN	B-NP	B-protein
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
acute	acute	JJ	I-NP	O
changes	change	NNS	I-NP	O
from	from	IN	B-PP	O
prior	prior	RB	B-NP	O
.	.	.	O	O

ASSESSMENT	ASSESSMENT	NN	B-NP	O
AND	AND	CC	I-NP	O
PLAN	PLAN	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
65-year-old	65-year-old	JJ	I-NP	O
male	male	NN	I-NP	O
with	with	IN	B-PP	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
COPD	COPD	NN	B-NP	O
who	who	WP	B-NP	O
is	be	VBZ	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
COPD	COPD	NN	I-NP	O
exacerbation	exacerbation	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
likely	likely	JJ	I-NP	O
viral	viral	JJ	I-NP	O
URI	URI	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
some	some	DT	B-NP	O
mild	mild	JJ	I-NP	O
congestive	congestive	JJ	I-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
exacerbation	exacerbation	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
BY	BY	NNP	I-NP	O
SYSTEM	SYSTEM	NNP	I-NP	O
:	:	:	O	O
Pulmonary	Pulmonary	NNP	B-NP	O
:	:	:	O	O
As	As	IN	B-SBAR	O
noted	note	VBN	B-VP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
having	have	VBG	I-VP	O
hypercarbic	hypercarbic	JJ	B-NP	O
respiratory	respiratory	JJ	I-NP	O
failure	failure	NN	I-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
ABG	ABG	NN	I-NP	O
of	of	IN	B-PP	O
7.16	7.16	CD	B-NP	O
/	/	SYM	I-NP	O
98/89	98/89	CD	I-NP	O
on	on	IN	B-PP	O
3	3	CD	B-NP	O
L	L	NN	I-NP	O
nasal	nasal	JJ	I-NP	O
cannula	cannula	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
therefore	therefore	RB	I-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
and	and	CC	B-PP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
required	require	VBD	B-VP	O
intubation	intubation	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
respiratory	respiratory	JJ	I-NP	O
status	status	NN	I-NP	O
improved	improve	VBN	B-VP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
extubated	extubate	VBN	I-VP	O
on	on	IN	B-PP	O
11/5/2005	11/5/2005	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
Solu-Medrol	Solu-Medrol	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
to	to	TO	B-PP	O
prednisone	prednisone	NN	B-NP	O
on	on	IN	B-PP	O
4/20/2005	4/20/2005	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
thick	thick	JJ	B-NP	O
tenacious	tenacious	JJ	I-NP	O
secretions	secretion	NNS	I-NP	O
and	and	CC	O	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
concern	concern	NN	B-NP	O
for	for	IN	B-PP	O
possible	possible	JJ	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
underlying	underlying	JJ	I-NP	O
flare	flare	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
COPD	COPD	NN	I-NP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initiated	initiate	VBN	I-VP	O
on	on	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
14-day	14-day	JJ	I-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
,	,	,	O	O
upon	upon	IN	B-PP	O
presentation	presentation	NN	B-NP	O
,	,	,	O	O
been	be	VBN	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
mildly	mildly	RB	B-NP	O
volume	volume	NN	I-NP	O
overloaded	overload	VBD	B-VP	O
but	but	CC	O	O
this	this	DT	B-NP	O
improved	improve	VBN	B-VP	O
with	with	IN	B-PP	O
diuresis	diuresis	NN	B-NP	O
prior	prior	JJ	B-ADVP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
MICU	MICU	NNP	I-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
intubation	intubation	NN	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
pH	pH	NN	I-NP	O
corrected	correct	VBD	B-VP	O
slowly	slowly	RB	B-ADVP	O
,	,	,	O	O
but	but	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
still	still	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
markedly	markedly	RB	B-NP	O
elevated	elevated	JJ	I-NP	O
partial	partial	JJ	I-NP	O
CO2	CO2	NN	I-NP	O
pressures	pressure	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
chest	chest	NN	B-NP	O
PT	PT	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
Duonebs	Duoneb	NNS	B-NP	O
.	.	.	O	O

Following	Follow	VBG	B-PP	O
extubation	extubation	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
floor	floor	NN	I-NP	O
and	and	CC	O	O
did	do	VBD	B-VP	O
well	well	RB	B-ADVP	O
.	.	.	O	O

Medications	Medication	NNS	B-NP	O
were	be	VBD	B-VP	O
adjusted	adjust	VBN	I-VP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
prednisone	prednisone	NN	I-NP	O
taper	taper	NN	I-NP	O
,	,	,	O	O
Spiriva	Spiriva	NNP	B-NP	O
,	,	,	O	O
Advair	Advair	NNP	B-NP	O
250/50	250/50	CD	I-NP	O
Diskus	Diskus	NNP	I-NP	O
,	,	,	O	O
supplemental	supplemental	JJ	B-NP	O
oxygen	oxygen	NN	I-NP	O
,	,	,	O	O
Duonebs	Duoneb	NNS	B-NP	O
,	,	,	O	O
and	and	CC	O	O
albuterol	albuterol	NN	B-NP	O
nebulizers	nebulizer	NNS	I-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
improve	improve	VB	I-VP	O
,	,	,	O	O
and	and	CC	O	O
on	on	IN	B-PP	O
9/3/2005	9/3/2005	CD	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
ambulate	ambulate	VB	I-VP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
without	without	IN	B-PP	O
dyspnea	dyspnea	NN	B-NP	O
or	or	CC	I-NP	O
hypoxia	hypoxia	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
suggest	suggest	VBP	B-VP	O
outpatient	outpatient	NN	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
function	function	NN	I-NP	O
tests	test	NNS	I-NP	O
to	to	TO	B-VP	O
further	further	RB	I-VP	O
evaluate	evaluate	VB	I-VP	O
the	the	DT	B-NP	O
extent	extent	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
obstructive	obstructive	JJ	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
Ischemia	Ischemia	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
underwent	undergo	VBD	B-VP	O
a	a	DT	B-NP	O
negative	negative	JJ	I-NP	O
rule	rule	NN	I-NP	O
out	out	IN	B-PP	O
MI	MI	NN	B-NP	O
upon	upon	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
newly	newly	RB	I-NP	O
decreased	decrease	VBN	I-NP	O
EF	EF	NN	I-NP	B-protein
of	of	IN	B-PP	O
35	35	CD	B-NP	O
to	to	TO	I-NP	O
40	40	CD	I-NP	O
%	%	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
on	on	IN	B-PP	O
echocardiogram	echocardiogram	NN	B-NP	O
upon	upon	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
not	not	RB	I-VP	O
had	have	VBN	I-VP	O
any	any	DT	B-NP	O
ischemic	ischemic	JJ	I-NP	O
symptoms	symptom	NNS	I-NP	O
;	;	:	O	O
however	however	RB	O	O
,	,	,	O	O
this	this	DT	B-NP	O
marked	marked	JJ	I-NP	O
decrease	decrease	NN	I-NP	O
is	be	VBZ	B-VP	O
concerning	concern	VBG	I-VP	O
especially	especially	RB	B-ADVP	O
including	include	VBG	B-PP	O
the	the	DT	B-NP	O
inferior	inferior	JJ	I-NP	O
and	and	CC	I-NP	O
posterior	posterior	JJ	I-NP	O
wall	wall	NN	I-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
new	new	JJ	B-ADJP	O
from	from	IN	B-PP	O
his	his	PRP$	B-NP	O
prior	prior	JJ	I-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
beta-blocker	beta-blocker	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
statin	statin	NN	B-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
was	be	VBD	B-VP	O
reinitiated	reinitiate	VBN	I-VP	O
when	when	WRB	B-ADVP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
creatinine	creatinine	NN	I-NP	O
stabilized	stabilize	VBD	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
likely	likely	RB	I-VP	O
need	need	VB	I-VP	O
further	further	JJ	B-NP	O
cardiac	cardiac	JJ	I-NP	O
risk	risk	NN	I-NP	O
stratification	stratification	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
to	to	TO	B-VP	O
include	include	VB	I-VP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
stress	stress	NN	I-NP	O
test	test	NN	I-NP	O
.	.	.	O	O

Pump	Pump	NN	B-NP	O
:	:	:	O	O
As	As	IN	B-SBAR	O
mentioned	mention	VBN	B-VP	O
,	,	,	O	O
upon	upon	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
mild	mild	JJ	B-NP	O
volume	volume	NN	I-NP	O
overload	overload	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diastolic	diastolic	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
prior	prior	JJ	I-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
showing	show	VBG	B-VP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	B-protein
of	of	IN	B-PP	O
50	50	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
noted	note	VBN	B-VP	O
,	,	,	O	O
the	the	DT	B-NP	O
most	most	RBS	I-NP	O
recent	recent	JJ	I-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
obtained	obtain	VBN	B-VP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
shows	show	VBZ	B-VP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	B-protein
of	of	IN	B-PP	O
35	35	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
diffuse	diffuse	JJ	B-NP	O
global	global	JJ	I-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
and	and	CC	O	O
inferior	inferior	JJ	B-NP	O
posterior	posterior	JJ	I-NP	O
wall	wall	NN	I-NP	O
akinesis	akinesis	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
mild	mild	JJ	B-NP	O
decreased	decrease	VBN	I-NP	O
function	function	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
RV	RV	NN	I-NP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
,	,	,	O	O
and	and	CC	O	O
mild	mild	JJ	B-NP	O
left	left	JJ	I-NP	O
atrial	atrial	JJ	I-NP	O
enlargement	enlargement	NN	I-NP	O
and	and	CC	O	O
mild	mild	JJ	B-NP	O
right	right	JJ	I-NP	O
atrial	atrial	JJ	I-NP	O
enlargement	enlargement	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
relatively	relatively	RB	B-NP	O
stable	stable	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
hypertension	hypertension	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
PA	PA	NN	I-NP	O
pressure	pressure	NN	I-NP	O
of	of	IN	B-PP	O
50	50	CD	B-NP	O
plus	plus	CC	O	O
right	right	JJ	B-NP	O
atrial	atrial	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
diuresed	diurese	VBN	I-VP	O
aggressively	aggressively	RB	B-ADVP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
room	room	NN	I-NP	O
and	and	CC	O	O
therefore	therefore	RB	B-ADVP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
require	require	VB	I-VP	O
additional	additional	JJ	B-NP	O
diuresis	diuresis	NN	I-NP	O
upon	upon	IN	B-PP	O
transfer	transfer	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initiated	initiate	VBN	I-VP	O
on	on	IN	B-PP	O
hydralazine	hydralazine	NN	B-NP	O
and	and	CC	I-NP	O
Isordil	Isordil	NN	I-NP	O
for	for	IN	B-PP	O
afterload	afterload	JJ	B-NP	O
reduction	reduction	NN	I-NP	O
.	.	.	O	O

When	When	WRB	B-ADVP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
creatinine	creatinine	NN	I-NP	O
stabilized	stabilize	VBD	B-VP	O
,	,	,	O	O
these	these	DT	B-NP	O
were	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
an	an	DT	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
beta-blocker	beta-blocker	NN	I-NP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
half	half	NN	B-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
at	at	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
160	160	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
as	as	IN	B-PP	O
of	of	IN	B-PP	O
1/6/2006	1/6/2006	CD	B-NP	O
when	when	WRB	B-ADVP	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
mildly	mildly	RB	B-ADJP	O
hypervolemic	hypervolemic	JJ	I-ADJP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
significant	significant	JJ	B-NP	O
hypertension	hypertension	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
a	a	DT	B-NP	O
workup	workup	NN	I-NP	O
previously	previously	RB	B-ADVP	O
for	for	IN	B-PP	O
secondary	secondary	JJ	B-NP	O
causes	cause	NNS	I-NP	O
of	of	IN	B-PP	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
included	include	VBD	B-VP	O
a	a	DT	B-NP	O
negative	negative	JJ	I-NP	O
MRA	MRA	NN	I-NP	O
in	in	IN	B-PP	O
2004	2004	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
clonodine	clonodine	NN	I-NP	O
patch	patch	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
beta-blocker	beta-blocker	NN	B-NP	O
,	,	,	O	O
ACE	ACE	NN	B-NP	O
inhibitor	inhibitor	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
Imdur	Imdur	NNP	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
home	home	NN	I-NP	O
medication	medication	NN	I-NP	O
of	of	IN	B-PP	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
,	,	,	O	O
as	as	IN	B-SBAR	O
was	be	VBD	B-VP	O
the	the	DT	B-NP	O
amiloride	amiloride	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
may	may	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
reinitiated	reinitiate	VBN	I-VP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

Rhythm	Rhythm	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
four	four	CD	B-NP	O
beats	beat	NNS	I-NP	O
of	of	IN	B-PP	O
nonsustained	nonsustained	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
tachycardia	tachycardia	NN	I-NP	O
on	on	IN	B-PP	O
11/7/2005	11/7/2005	CD	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
resolved	resolve	VBD	B-VP	O
with	with	IN	B-PP	O
aggressive	aggressive	JJ	B-NP	O
electrolyte	electrolyte	NN	I-NP	O
replacement	replacement	NN	I-NP	O
.	.	.	O	O

While	While	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NNP	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
single	single	JJ	I-NP	O
run	run	NN	I-NP	O
of	of	IN	B-PP	O
30	30	CD	B-NP	O
beats	beat	NNS	I-NP	O
of	of	IN	B-PP	O
nonsustained	nonsustained	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
tachycardia	tachycardia	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
improved	improve	VBD	B-VP	O
with	with	IN	B-PP	O
electrolyte	electrolyte	NN	B-NP	O
replacement	replacement	NN	I-NP	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diabetes	diabete	NNS	B-NP	O
and	and	CC	O	O
therefore	therefore	RB	B-ADVP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
regimen	regimen	NN	I-NP	O
of	of	IN	B-PP	O
NPH	NPH	NN	B-NP	B-protein
initially	initially	RB	B-ADVP	O
at	at	IN	B-PP	O
20	20	CD	B-NP	O
units	unit	NNS	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
episode	episode	NN	I-NP	O
of	of	IN	B-PP	O
hypoglycemia	hypoglycemia	NN	B-NP	O
with	with	IN	B-PP	O
blood	blood	NN	B-NP	O
sugars	sugar	NNS	I-NP	O
around	around	IN	B-PP	O
40	40	CD	B-NP	O
and	and	CC	I-NP	O
therefore	therefore	RB	I-NP	O
the	the	DT	B-NP	O
NPH	NPH	NN	I-NP	B-protein
was	be	VBD	B-VP	O
decreased	decrease	VBN	I-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
regimen	regimen	NN	I-NP	O
of	of	IN	B-PP	O
15	15	CD	B-NP	O
units	unit	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
morning	morning	NN	I-NP	O
and	and	CC	O	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
hyperparathyroidism	hyperparathyroidism	NN	B-NP	O
likely	likely	RB	B-ADJP	O
from	from	IN	B-PP	O
renal	renal	JJ	B-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
therefore	therefore	RB	B-ADJP	O
secondary	secondary	JJ	I-ADJP	O
versus	versus	IN	B-PP	O
tertiary	tertiary	JJ	B-NP	O
hyperparathyroidism	hyperparathyroidism	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
therefore	therefore	RB	I-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
calcitriol	calcitriol	NN	B-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
stage	stage	NN	B-NP	O
IV	IV	CD	I-NP	O
chronic	chronic	JJ	I-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
oliguric	oliguric	JJ	B-ADJP	O
.	.	.	O	O

This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
likely	likely	RB	B-ADJP	O
due	due	JJ	I-ADJP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
prerenal	prerenal	JJ	I-NP	O
state	state	NN	I-NP	O
given	give	VBN	B-VP	O
diuresis	diuresis	NN	B-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
and	and	CC	O	O
further	further	RB	B-VP	O
exacerbated	exacerbate	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
underlying	underlie	VBG	I-NP	O
renal	renal	JJ	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

Bladder	Bladder	NN	B-NP	O
scan	scan	NN	I-NP	O
was	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
which	which	WDT	B-NP	O
only	only	RB	B-ADVP	O
showed	show	VBD	B-VP	O
3	3	CD	B-NP	O
mL	mL	NN	I-NP	O
of	of	IN	B-PP	O
urine	urine	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
bladder	bladder	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
urine	urine	NN	I-NP	O
output	output	NN	I-NP	O
increased	increase	VBD	B-VP	O
with	with	IN	B-PP	O
afterload	afterload	JJ	B-NP	O
reduction	reduction	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
acute-on-chronic	acute-on-chronic	JJ	B-NP	O
respiratory	respiratory	JJ	I-NP	O
acidosis	acidosis	NN	I-NP	O
with	with	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
bicarbonate	bicarbonate	NN	I-NP	O
compensation	compensation	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
anion	anion	NN	I-NP	O
gap	gap	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
lactate	lactate	NN	I-NP	O
was	be	VBD	B-VP	O
measured	measure	VBN	I-VP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
only	only	RB	B-NP	O
0.6	0.6	CD	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
.	.	.	O	O

Throughout	Throughout	IN	B-PP	O
the	the	DT	B-NP	O
remainder	remainder	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
creatinine	creatinine	NN	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
improve	improve	VB	I-VP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
measured	measure	VBN	I-VP	O
at	at	IN	B-PP	O
3.4	3.4	CD	B-NP	O
on	on	IN	B-PP	O
1/6/2006	1/6/2006	CD	B-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
renal	renal	JJ	I-NP	O
consult	consult	NN	I-NP	O
was	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

They	They	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
feel	feel	VB	I-VP	O
that	that	IN	B-SBAR	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
any	any	DT	B-NP	O
indication	indication	NN	I-NP	O
for	for	IN	B-PP	O
acute	acute	JJ	B-NP	O
renal	renal	JJ	I-NP	O
replacement	replacement	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
continue	continue	VB	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
renally	renally	RB	B-NP	O
dosed	dose	VBN	I-NP	O
meds	med	NNS	I-NP	O
and	and	CC	O	O
continue	continue	VBP	B-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
renal	renal	JJ	I-NP	O
diet	diet	NN	I-NP	O
,	,	,	O	O
including	include	VBG	B-PP	O
Phoslo	Phoslo	NNP	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
have	have	VB	I-VP	O
close	close	JJ	B-NP	O
renal	renal	JJ	I-NP	O
followup	followup	NN	I-NP	O
within	within	IN	B-PP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
few	few	JJ	I-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

Hematologic	Hematologic	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
iron	iron	NN	B-NP	O
deficiency	deficiency	NN	I-NP	O
anemia	anemia	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
ferrous	ferrous	JJ	B-NP	O
sulfate	sulfate	NN	I-NP	O
supplementation	supplementation	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
an	an	DT	B-NP	O
EPO	EPO	NN	I-NP	B-protein
level	level	NN	I-NP	O
is	be	VBZ	B-VP	O
still	still	RB	I-VP	O
pending	pende	VBG	I-VP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initiated	initiate	VBN	I-VP	O
on	on	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
14-day	14-day	JJ	I-NP	O
course	course	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
4/13/2005	4/13/2005	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
completed	complete	VBN	I-VP	O
as	as	IN	B-PP	O
of	of	IN	B-PP	O
9/11/2006	9/11/2006	CD	B-NP	O
.	.	.	O	O

Blood	Blood	NN	B-NP	O
cultures	culture	NNS	I-NP	O
and	and	CC	O	O
sputum	sputum	NN	B-NP	O
cultures	culture	NNS	I-NP	O
were	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
and	and	CC	O	O
are	be	VBP	B-VP	O
negative	negative	JJ	B-ADJP	O
to	to	TO	B-PP	O
date	date	NN	B-NP	O
.	.	.	O	O

Influenza/adenovirus/RSV	Influenza/adenovirus/RSV	NN	B-NP	B-protein
swabs	swab	NNS	I-NP	I-protein
were	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
and	and	CC	O	O
were	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

Prophylaxis	Prophylaxis	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
received	receive	VBD	B-VP	O
heparin	heparin	NN	B-NP	B-protein
subcutaneous	subcutaneous	JJ	I-NP	I-protein
5000	5000	CD	I-NP	I-protein
units	unit	NNS	I-NP	I-protein
t.i.d.	t.i.d.	VBN	B-VP	O
for	for	IN	B-PP	O
DVT	DVT	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
Pepcid	Pepcid	NN	B-NP	O
for	for	IN	B-PP	O
GI	GI	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
evaluated	evaluate	VBN	I-VP	O
by	by	IN	B-PP	O
physical	physical	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
and	and	CC	O	O
felt	feel	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
at	at	IN	B-PP	O
his	his	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
ambulate	ambulate	VB	I-VP	O
and	and	CC	I-VP	O
maintain	maintain	VB	I-VP	O
his	his	PRP$	B-NP	O
pulse	pulse	NN	I-NP	O
oxymetry	oxymetry	NN	I-NP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
93	93	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	B-PP	O
home	home	NN	B-NP	O
with	with	IN	B-PP	O
visiting	visit	VBG	B-VP	O
nurse	nurse	NN	B-NP	O
service	service	NN	I-NP	O
.	.	.	O	O

TO	TO	TO	B-PP	B-protein
DO	DO	NNP	B-NP	I-protein
:	:	:	O	I-protein
1	1	CD	B-NP	I-protein
.	.	.	O	O

VNA	VNA	NN	B-NP	B-protein
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
check	check	VB	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
,	,	,	O	O
oxygen	oxygen	NN	B-NP	O
saturation	saturation	NN	I-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
check	check	NN	B-NP	O
weekly	weekly	JJ	I-NP	O
electrolytes	electrolyte	NNS	I-NP	O
and	and	CC	O	O
creatinine	creatinine	NN	B-NP	O
levels	level	NNS	I-NP	O
and	and	CC	O	O
call	call	VB	B-VP	O
results	result	NNS	B-NP	O
to	to	TO	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Loil	Loil	NNP	I-NP	O
office	office	NN	I-NP	O
at	at	IN	B-PP	O
890-189-0562	890-189-0562	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Johanns	Johanns	NNP	I-NP	O
within	within	IN	B-PP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
week	week	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
his	his	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
meds	med	NNS	I-NP	O
titrated	titrate	VBN	B-VP	O
up	up	RP	B-PRT	O
as	as	RB	O	O
needed	need	VBN	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
may	may	MD	B-VP	O
require	require	VB	I-VP	O
increased	increase	VBN	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Lasix	Lasix	NN	B-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
amiloride	amiloride	NN	I-NP	O
and	and	CC	I-NP	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	O
may	may	MD	B-VP	O
be	be	VB	I-VP	O
resumed	resume	VBN	I-VP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
cardiology	cardiology	NN	I-NP	O
outpatient	outpatient	NN	I-NP	O
followup	followup	NN	I-NP	O
regarding	regard	VBG	B-VP	O
his	his	PRP$	B-NP	O
decreased	decrease	VBN	I-NP	O
EF	EF	NN	I-NP	B-protein
and	and	CC	O	O
new	new	JJ	B-NP	O
wall	wall	NN	I-NP	O
motion	motion	NN	I-NP	O
abnormalities	abnormality	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
may	may	MD	B-VP	O
require	require	VB	I-VP	O
stress	stress	NN	B-NP	O
imaging	imaging	NN	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
cardiac	cardiac	JJ	I-NP	O
risk	risk	NN	I-NP	O
stratification	stratification	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
renal	renal	JJ	B-ADJP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
regarding	regard	VBG	B-VP	O
his	his	PRP$	B-NP	O
chronic	chronic	JJ	I-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
and	and	CC	O	O
future	future	JJ	B-NP	O
need	need	NN	I-NP	O
for	for	IN	B-PP	O
hemodialysis	hemodialysis	NN	B-NP	O
.	.	.	O	O

ADDITIONAL	ADDITIONAL	JJ	B-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
Continue	Continue	NN	B-NP	O
to	to	TO	B-VP	O
take	take	VB	I-VP	O
all	all	DT	B-NP	O
of	of	IN	B-PP	O
your	your	PRP$	B-NP	O
medications	medication	NNS	I-NP	O
,	,	,	O	O
including	include	VBG	B-PP	O
the	the	DT	B-NP	O
Spiriva	Spiriva	NNP	I-NP	O
and	and	CC	I-NP	O
Advair	Advair	NNP	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
replace	replace	VBP	B-VP	O
the	the	DT	B-NP	O
Flovent	Flovent	NNP	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
the	the	DT	B-NP	O
prednisone	prednisone	NN	I-NP	O
.	.	.	O	O

Follow	Follow	VB	B-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Lapeyrouse	Lapeyrouse	NNP	I-NP	O
within	within	IN	B-PP	O
one	one	CD	B-NP	O
week	week	NN	I-NP	O
.	.	.	O	O

Participate	Participate	NN	B-NP	O
with	with	IN	B-PP	O
your	your	PRP$	B-NP	O
visiting	visit	VBG	I-NP	O
nurse	nurse	NN	I-NP	O
services	service	NNS	I-NP	O
.	.	.	O	O

Seek	Seek	JJ	B-NP	O
medical	medical	JJ	I-NP	O
attention	attention	NN	I-NP	O
for	for	IN	B-PP	O
increased	increase	VBN	B-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
fever	fever	NN	B-NP	O
,	,	,	O	O
chills	chill	NNS	B-NP	O
,	,	,	O	O
or	or	CC	O	O
any	any	DT	B-NP	O
other	other	JJ	I-NP	O
concerns	concern	NNS	I-NP	O
.	.	.	O	O

Weigh	Weigh	VB	B-VP	O
yourself	yourself	PRP	B-NP	O
daily	daily	RB	B-ADVP	O
and	and	CC	O	O
contact	contact	VB	B-VP	O
your	your	PRP$	B-NP	O
doctor	doctor	NN	I-NP	O
if	if	IN	B-SBAR	O
you	you	PRP	B-NP	O
gain	gain	VBP	B-VP	O
more	more	JJR	B-NP	O
than	than	IN	I-NP	O
2	2	CD	I-NP	O
pounds	pound	NNS	I-NP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
or	or	CC	O	O
5	5	CD	B-NP	O
pounds	pound	NNS	I-NP	O
within	within	IN	B-PP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
Mechanical	Mechanical	JJ	B-NP	O
soft	soft	JJ	I-NP	O
,	,	,	I-NP	O
thin	thin	JJ	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
added	add	VBN	I-NP	O
salt	salt	NN	I-NP	O
,	,	,	O	O
ADA	ADA	NN	B-NP	O
2100	2100	CD	B-NP	O
calories	calorie	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
,	,	,	O	O
renal	renal	JJ	B-NP	O
diet	diet	NN	I-NP	O
.	.	.	O	O

ACTIVITY	ACTIVITY	NN	B-NP	O
:	:	:	O	O
Walking	Walk	VBG	B-VP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-VP	O
.	.	.	O	O

FOLLOW-UP	FOLLOW-UP	JJ	B-NP	O
APPOINTMENTS	APPOINTMENTS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Duceman	Duceman	NNP	I-NP	O
,	,	,	O	O
internal	internal	JJ	B-NP	O
medicine	medicine	NN	I-NP	O
,	,	,	O	O
within	within	IN	B-PP	O
one	one	CD	B-NP	O
week	week	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Rylander	Rylander	NNP	I-NP	O
,	,	,	O	O
nephrology	nephrology	NN	B-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
2/14/2006	2/14/2006	CD	B-NP	O
at	at	IN	B-PP	O
1	1	CD	B-NP	O
:	:	SYM	O	O
30	30	CD	B-NP	O
p.m.	p.m.	NN	I-NP	O
3	3	CD	I-NP	O
.	.	.	O	O

Podiatry	Podiatry	NN	B-NP	O
on	on	IN	B-PP	O
1/13/2006	1/13/2006	CD	B-NP	O
at	at	IN	B-PP	O
3	3	CD	B-NP	O
:	:	SYM	O	O
30	30	CD	B-NP	O
p.m.	p.m.	NN	I-NP	O
4	4	CD	B-NP	O
.	.	.	O	O

Cardiology	Cardiology	NN	B-NP	O
within	within	IN	B-PP	O
three	three	CD	B-NP	O
to	to	TO	I-NP	O
four	four	CD	I-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-ADJP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Calcitriol	Calcitriol	NN	B-NP	O
0.5	0.5	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Phoslo	Phoslo	NN	B-NP	B-protein
667	667	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
t.i.d.	t.i.d.	NN	I-NP	I-protein
4	4	CD	I-NP	I-protein
.	.	.	O	O

Clonodine	Clonodine	NN	B-NP	O
0.2	0.2	CD	I-NP	O
mg	mg	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
topical	topical	JJ	B-NP	O
patch	patch	NN	I-NP	O
q.	q.	NN	I-NP	O
week	week	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Ferrous	Ferrous	JJ	B-NP	B-protein
sulfate	sulfate	NN	I-NP	I-protein
325	325	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
t.i.d.	t.i.d.	NN	I-NP	I-protein
6	6	CD	I-NP	I-protein
.	.	.	O	O

Lasix	Lasix	NN	B-NP	O
160	160	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Insulin	Insulin	NN	B-NP	B-protein
NPH	NPH	NN	I-NP	I-protein
15	15	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
subcutaneous	subcutaneous	JJ	B-NP	I-protein
q.a.m.	q.a.m.	NN	I-NP	I-protein
8	8	CD	I-NP	I-protein
.	.	.	O	O

Insulin	Insulin	NN	B-NP	B-protein
NPH	NPH	NN	I-NP	I-protein
10	10	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
subcutaneous	subcutaneous	JJ	B-NP	I-protein
q.p.m.	q.p.m.	NN	I-NP	I-protein
9	9	CD	I-NP	I-protein
.	.	.	O	O

Labetalol	Labetalol	NN	B-NP	O
600	600	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

Lisinopril	Lisinopril	NNP	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Imdur	Imdur	NN	B-NP	O
ER	ER	NN	I-NP	O
30	30	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Levofloxacin	Levofloxacin	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
48	48	CD	I-NP	O
h.	h.	NN	I-NP	O
x2	x2	NN	I-NP	O
week	week	NN	I-NP	O
course	course	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
completed	complete	VBN	I-VP	O
as	as	IN	B-PP	O
of	of	IN	B-PP	O
8/8/2005	8/8/2005	CD	B-NP	O
,	,	,	O	O
next	next	JJ	B-NP	O
dose	dose	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
administered	administer	VBN	I-VP	O
on	on	IN	B-PP	O
1/13/2006	1/13/2006	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
9/17/2006	9/17/2006	CD	B-NP	O
and	and	CC	O	O
then	then	RB	B-NP	O
8/13/2006	8/13/2006	CD	I-NP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Advair	Advair	NNP	B-NP	O
Diskus	Diskus	NNP	I-NP	O
250/50	250/50	CD	I-NP	O
one	one	CD	I-NP	O
puff	puff	NN	I-NP	O
inhaled	inhale	VBD	B-VP	O
b.i.d.	b.i.d.	RB	B-NP	O
14	14	CD	I-NP	O
.	.	.	O	O

Spiriva	Spiriva	NN	B-NP	O
18	18	CD	I-NP	O
mcg	mcg	NN	I-NP	O
inhaled	inhale	VBD	B-VP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

Prednisone	Prednisone	NN	B-NP	O
taper	taper	NN	I-NP	O
starting	start	VBG	B-VP	O
as	as	IN	B-SBAR	O
of	of	IN	B-PP	O
1/2/06	1/2/06	CD	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
daily	daily	JJ	I-NP	O
x1	x1	NN	I-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
then	then	RB	O	O
20	20	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
daily	daily	JJ	I-NP	O
x2	x2	NN	I-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
10	10	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
daily	daily	JJ	I-NP	O
x2	x2	NN	I-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
5	5	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
daily	daily	JJ	I-NP	O
x2	x2	NN	I-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
then	then	RB	B-ADVP	O
stop	stop	VB	B-VP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Albuterol	Albuterol	NNP	B-NP	O
inhaler	inhaler	IN	B-PP	O
two	two	CD	B-NP	O
puffs	puff	NNS	I-NP	O
inhaled	inhale	VBD	B-VP	O
q.i.d.	q.i.d.	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
for	for	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Albuterol	Albuterol	NNP	B-NP	O
nebulizer	nebulizer	IN	B-PP	O
2.5	2.5	CD	B-NP	O
mg	mg	NN	I-NP	O
nebulized	nebulize	VBD	B-VP	O
q.	q.	NN	B-NP	O
4	4	CD	I-NP	O
h.	h.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
for	for	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
7-5506486	7-5506486	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
TREFF	TREFF	NN	B-NP	B-protein
,	,	,	O	O
TYRONE	TYRONE	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
FEHRINGER	FEHRINGER	NNP	B-NP	O
,	,	,	O	O
MYRON	MYRON	NNP	B-NP	O
BENNETT	BENNETT	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
2445312	2445312	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
5/17/06	5/17/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
5/17/06	5/17/06	CD	B-NP	O

